Updated Jul 16, 2026
ZACCARDELLI DAVID has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $11.26M.
David Zaccardelli is the President and CEO of Verona Pharma plc, a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. He has been involved in the company as a director and has participated in various SEC filings related to his role.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-10-07 | VRNA | Verona Pharma plc | D — Derivative transaction | 3.29M | — | |
| 2025-10-07 | VRNA | Verona Pharma plc | M — Option exercise | 3.29M | — | |
| 2025-10-07 | VRNA | Verona Pharma plc | D — Derivative transaction | 12.18M | — | |
| 2025-08-29 | VRNA | Verona Pharma plc | G — Bona-fide gift | 1.20M | $0.00 | |
| 2025-08-01 | VRNA | Verona Pharma plc | S — Open-market sale | 208.9K | $13.14 | $2.75M |
| 2025-08-01 | VRNA | Verona Pharma plc | M — Option exercise | 255.7K | $0.00 | |
| 2025-07-07 | VRNA | Verona Pharma plc | F — Tax withholding / forfeiture | 90.3K | $11.44 | $1.03M |
| 2025-07-07 | VRNA | Verona Pharma plc | M — Option exercise | 229.5K | $0.00 | |
| 2024-12-06 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 162.8K | $5.01 | $815K |
| 2024-12-06 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 640.3K | $5.01 | $3.21M |
| 2024-12-06 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 67.6K | $5.00 | $338K |
| 2024-12-02 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 3.2K | $5.00 | $16K |
| 2024-12-02 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 98.9K | $5.01 | $495K |
| 2024-12-02 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 23.2K | $5.00 | $116K |
| 2024-11-26 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 1.6K | $5.00 | $8K |
| 2024-11-13 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 2.4K | $5.00 | $12K |
| 2024-11-05 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 94.1K | $4.39 | $413K |
| 2024-11-05 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 46.9K | $4.38 | $205K |
| 2024-11-01 | VRNA | Verona Pharma plc | F — Tax withholding / forfeiture | 246.0K | $4.24 | $1.04M |
| 2024-11-01 | VRNA | Verona Pharma plc | A — Grant or award | 200.0K | $0.00 |
David Zaccardelli is the President and CEO of Verona Pharma plc, a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. He has been involved in the company as a director and has participated in various SEC filings related to his role.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 17 open-market sales ($11.26M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live ZACCARDELLI DAVID profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.